Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Ublituximab [USAN:INN]
RN: 1174014-05-1
UNII: U59UGK3IPC

Note

  • NCI: A chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ublituximab specifically binds to the B cell-specific cell surface antigen CD20, thereby potentially inducing a B cell-directed complement dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) against CD20-expressing B cells, leading to B cell apoptosis. CD20 is a non-glycosylated cell surface phosphoprotein that is exclusively expressed on B cells during most stages of B cell development and is often overexpressed in B-cell malignancies. Ublituximab has a specific glycosylation profile, with a low fucose content, that may enhance its ADCC response against malignant B cells. (NCI Thesaurus)

Molecular Formula

  • C6418-H9866-N1702-O2006-S48
 

Classification Code

  • Treatment of Cancer, Autoimmune Disorders
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Ublituximab
  • Ublituximab [USAN:INN]

Synonyms

  • Immunoglobulin G1, anti-(human cd20 (antigen)) (human-mouse monoclonal gamma1-chain), disulfide with human-mouse monoclonal kappa-chain, dimer
  • LFB-R603
  • TG-1101
  • Ublituximab
  • UNII-U59UGK3IPC

Registry Numbers

CAS Registry Number

  • 1174014-05-1

FDA UNII

  • U59UGK3IPC

System Generated Number

  • 1174014051